Innocoll to Report Second Quarter 2016 Financial Results and Host Webcast and Conference Call on August 17, 2016
Interested parties may access the live webcast and call through the Investors section of the company website at www.innocoll.com or directly through the registration link. A recording will be archived on the company website for 90 days.
The live call may be accessed by dialing 877-407-4018 for domestic callers and 201-689-8471 for international callers. A telephone replay of the call will be available until
Our currently approved products include: COLLAGUARD® (ex-US), COLLATAMP® G, SEPTOCOLL® E, REGENEPRO®, COLLACARE®, COLLEXA®, and ZORPREVA®, some of which are sold globally through strategic partnerships, including those with Takeda, EUSA Pharma, Biomet 3i and Biomet. All of our native collagen products —from extraction/purification of type-1 collagen through final delivery form — are manufactured at our certified, integrated plant in Saal, Germany.
For more information, please visit www.innocoll.com.
CollaRx®, Collatamp®, COLLAGUARD®, Collieva®, CollaCare®, Collexa®, COGENZIA® LidoColl®, LiquiColl®, and XARACOLL® are registered trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are trademarks of the company.
Pepe CarmonaChief Financial Officer (215) 983-3362 firstname.lastname@example.org Jeannie Sorenson, M.D.Vice President, Investor Relations (314) 458-7355 email@example.com